JOSEPH A. FRANCIOSA, M.D.
This content is PDF only. Please click on the PDF icon to access.
Amrinone is a nonglycosidic, non-catecholamine-dependent, inotropic vasodilator agent that has recently been made available for intravenous use in patients with severe heart failure. Because other agents, such as dopamine, dobutamine, and nitroprusside, are available and have actions similar to those of amrinone in patients with heart failure, the usefulness of this newer agent must be put in perspective.
Amrinone is advertised as a "major advance" in inotropic therapy because of its alleged advantages of more sustained action than dopamine or dobutamine and reduction of myocardial oxygen demand. The evidence for these claims and their importance appears minimal. Recent reports indicate
FRANCIOSA JA. Intravenous Amrinone: An Advance or a Wrong Step?. Ann Intern Med. 1985;102:399–400. doi: https://doi.org/10.7326/0003-4819-102-3-399
Download citation file:
Published: Ann Intern Med. 1985;102(3):399-400.
Results provided by:
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use